
Seaport Therapeutics Begins Phase 1 Trial of GlyphAgo™ (SPT-320)
Seaport Therapeutics a clinical-stage biopharmaceutical company developing next-generation neuropsychiatric medicines, announced that the first participant has been dosed in its Phase 1 clinical study of GlyphAgo™ (SPT-320 or Glyph Agomelatine). GlyphAgo is a novel “Glyphed” oral prodrug of agomelatine designed…